Standard BioTools Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Standard BioTools Inc. (LAB) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$20.23 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-16
- Standard BioTools Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$20.23M.
- Standard BioTools Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$18.98M.
- Standard BioTools Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$15.58M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$20.23M 10-K · filed 2026-03-16 |
| 2024-12-31 | -$18.98M 10-K · filed 2026-03-16 |
| 2023-12-31 | -$15.58M 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |